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ABSTRACT 
 
Aim: To determine the effect of tea polyphenols and methotrexate on viability and reactive oxygen 
species (ROS) in a naturally resistant breast cancer cell line MDA-MB-231. 
Methodology: MDA-MB-231 cells were selected as a model for methotrexate resistant breast 
cancer. Drug tests were performed over 72 hours at concentrations 0-100 µM. Pre-treatments were 
with quercetin (QE) or epigallocatechin gallate (EGCG) for 5 hours followed by methotrexate. 
Cytotoxicity was measured using the MTT assay or resazurin fluorescence assay. ROS was 
determined using the 2’, 7’-dichlorofluorescein diacetate assay. Intracellular GSH was measured 
using the monochlorobimane assay. 
Results: Methotrexate was cytotoxic to MDA-MB-231 cells with IC50 of 35±4 µM. The IC50 value 
was 68±9.4 µM with QE and 83±16 µM for EGCG. The pre-treatment with QE and EGCG lowered 
the IC50 for methotrexate by 28% (P =0.009) and 16% (P=0.2027). Intracellular ROS 
concentrations increased after treatment with methotrexate, QE or EGCG singly and ROS 
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decreased with combination treatment compared with the response for methotrexate only. There 
were no significant changes in intracellular GSH.  
Conclusion: Pretreatment with tea polyphenols partially sensitized breast cancer cells towards 
methotrexate and decreases intracellular ROS. More research is needed to optimize the sensitizing 
effect of tea phenols on the breast cancer cell response to methotrexate. 
 
 
Keywords: Breast cancer; methotrexate; quercetin; epigallocatechin gallate; oxidative stress; 
anticancer effect. 
 
ABBREVIATIONS 
 
MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MTX – methotrexate; QE – 
quercetin; EGCG - epigallocatechin gallate; ROS - reactive oxygen species; GSH – glutathione; 
DMEM - dulbecco’s modified eagle’s medium; FBS - foetal bovine serum; DMSO – dimethyl sulfoxide; 
MTT - thiazolyl blue tetrazolium; PBS - phosphate buffer saline; DCFH-DA - 2’,7’-dichlorofluorescin 
diacetate; mCB – monochlorobimane; IC50 - 50% inhibitory concentrations; RFU - relative 
fluorescence units; HTA - human tissue authority. 
 
1. INTRODUCTION 
 
Methotrexate was introduced in the 1950s to 
treat neoplastic disorders. Low dose 
methotrexate is used for the treatment of 
autoimmune disorders such as rheumatoid 
arthritis [1]. As a folic acid analogue, 
methotrexate has an antagonistic effect on folic 
acid metabolism that results in the inhibition of 
DNA / RNA synthesis and cell division [1]. The 
mechanism of methotrexate action is not specific 
for malignant cells and other cells such as the 
haematopoietic cells of the bone marrow, 
intestinal mucosa cells, and hepatocytes have 
been found to be particularly susceptible to 
methotrexate toxicity. Methotrexate treatment 
leads to increased myeloperoxidase, elevated 
reactive oxygen species (ROS) and increased 
oxidative stress. There is considerable interest in 
the use of natural agents to ameliorate 
methotrexate induced oxidative damage [2,3]. 
 
Breast cancer is the second most common 
cancer death in women within the United 
Kingdom; the incidence of breast cancer 
increased 90% between the years 1997 and 
2010 [4]. The human breast cancer cell line 
MDA-MB-231 is oestrogen receptor negative and 
naturally resistant to methotrexate [5]. 
Methotrexate resistance in MDA-MB-231 cells is 
attributed to low levels ofreduced folate carrier 
expression [5].  
 
Recent investigations showed that combination 
treatments using methotrexate and natural 
antioxidants decreased the levels of drug-
induced oxidative damage [2,3]. However, the 
effect of antioxidants on methotrexate 
effectiveness has not been widely examined. Tea 
polyphenols exhibit antioxidant activity and, 
some like epigallocatechin gallate (EGCG) 
showed anticancer activity [6]. Recent 
investigations have demonstrated that tea 
polyphenols enhance the susceptibility of 
resistant breast cancer cells to anti-estrogen 
therapy [7], leading to their suggested use as 
adjuvants in cancer therapy [8]. However, few or 
no studies have appeared on the effects of tea 
polyphenols on methotrexate-induced oxidative 
stress or anticancer activity. A recent 
investigation showed that curcumin treatment 
can augment methotrexate cytotoxicity [9]. The 
hypothesis examined in this study is that pre-
treatment with non-toxic doses QE or EGCG will 
chemosensitize breast cancer cells towards 
methotrexate and lower the intracellular levels of 
ROS. The experimental design involved 
assessing the dose-response for a methotrexate 
using a resistant breast cancer (MDA-MB-231) 
cell line before and after pre-treatment QE or 
EGCG. The effect of tea phenols pre-treatment 
on intracellular ROS was also monitored. 
 
2. MATERIALS AND METHODS 
 
2.1 Cell Culture 
 
MDA-MB-231 cells (American Type Cell Culture) 
were cultured in Dulbecco’s modified eagle’s 
medium (DMEM; GIBCO) containing 10% foetal 
bovine serum (FBS) (Invitrogen) in 95% O2 and  
5% CO2 at 37ºC (LEEC research incubator, 
LEEC, UK). Cells were trypsinised, counted 
using the NucleoCounter (NC-3000, 
ChemoMetec, Denmark), inoculated to give 
10,000 cells/well and 50 µl media in 96-microwell 
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plates (Nunc; Roskilde, Denmark). The cells 
were then incubated overnight to allow cell 
attachment. 
 
2.2 Drug Tests 
 
Methotrexate (100 mM) QE (100 mM) or EGCG 
(40 mM) stock solutions were prepared in 
dimethyl sulfoxide (Sigma Aldrich) and stored at -
18ºC. Each stock solution was diluted 1/5 in 
DMEM media and filter-sterilised (Merck Millipore 
Ltd, Germany). Serial 1/10 dilutions of the sterile 
drug solutions were performed and 50µl of the 
various compounds were added to inoculated 
wells followed by incubation for 72 hours. At the 
highest drug concentrations tested (100 µM) the 
final DMSO concentration did not exceed 0.1% 
(v/v) which is not toxic to breast cancer cells.  As 
required by the experimental design, first the 
dose-response for MDA-MB-231 was determined 
by treating cells with methotrexate, QE or EGCG 
separately at concentrations of 0-100 µM. From 
this study, the non-toxic doses of QE and EGCG 
were established. Non-toxic concentrations of tea 
phenols (1-10 µM) were used to examine the 
effect of cell pre-treatments. 
 
2.3 MTT Assay for Cell Viability  
 
The Thiazolyl Blue Tetrazolium (MTT; Sigma-
Aldrich) assay was performed essentially as 
described previously [10]. MTT (5 mg/ ml) was 
dissolved in phosphate buffer saline (PBS) and 
filter-sterilised then stored in the dark at 4ºC. 
Cells treated with drug were washed three times 
with PBS (100 µl) and PBS left in the wells (100 
µl). MTT (20 µL) was added followed by 2 hours 
incubation. Isopropynol-0.04N HCl solution (100 
µl) was added and absorbance readings were 
taken at 570 nm (VERSA Max Micro plate reader; 
Molecular Devices, USA). 
 
2.4 Resazurin Assay for Cell Viability 
 
Resazurin (Sigma Aldrich) solution was prepared 
by dissolving 1.6 mg of resazurin in PBS (100 
mL). The stock solution was filter-sterilized and 
stored at room temperature. Pre-treatments 
using QE and EGCG and methotrexate drug test 
were performed as previously described. Cells 
were washed twice with ice cold PBS and 
resazurin was added (10 µl) followed by 
incubation for 2 hours. Fluorescence readings 
were recorded with and excitation and emission 
wavelength (λex/ λem) equal to 544 nm/ 620-10 
nm (Fluostar Omega Fluorescence Instrument; 
BMG-Lab-Tech, Germany). 
 
2.5 Determination of Intracellular 
Reaction Oxygen Species 
 
The concentration of intracellular reactive oxygen 
species (ROS) was determined using 2’,7’-
dichlorofluorescin diacetate (DCFH-DA). Breast 
cancer cells were seeded in microplate wells for 
24 hours and pre-treated with QE or EGCG for 5 
hours. The microplate wells were washed twice 
with media with 50 µl left in the wells. Varying 
concentrations of methotrexate (50µl) were 
added to the cells followed by incubation for 72 
hours. DCFH-DA (100µl) was added to the drug 
treated cells and cultures incubated for 2 hours. 
Fluorescence readings were read with λex/ λem 
=485 nm/ 520 nm. The reagent blank comprised 
cell-free microtitre plates containing 50 µl media 
and methotrexate and the DCFH-DA assay was 
performed as described above. ROS were also 
determined using MDA-MB-231 cells pre-loaded 
with DCFH-DA for short-term combination 
treatments. Cultured cells were treated with 
DCFH-DA (100 µl) and incubated for 1 hour. The 
microtitre plates were washed twice with PBS. 
The DCFH-preloaded cells were treated with 1 
uM of methotrexate and/ or QE or EGCG for 1 
hour and fluorescence readings were recording 
as above.   
 
2.6 Monochlorobimane Assay for 
Intracellular GSH 
 
Monochlorobimane (mCB) stock solution was 
prepared by dissolving 5 mg of mCB into 2 mL of 
methanol and stored at -18ºC.The microtitre 
plates were inoculated as previously described 
and then treated with drugs and incubated for 1 
hour. The microtitre plates were then washed 
twice with cold PBS (100 µl) and a further 100 µl 
of PBS was left in wells. Then 5 µl mCB was 
added to the wells and the microplate incubated 
for 2 hours at 37ºC. Fluorescence measurements 
were then recorded with λex/ λem equal to 355 
nm /520 nm. 
 
2.7 Statistical Analysis 
 
All experiments were repeated on 3 different 
occasions, with 6 replicates per drug 
concentration. Pooled data (n =18) were 
subjected to statistical analysis. One-way 
ANOVA tests were performed by Microsoft SPSS 
version 21 to analyse statistically significant 
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differences between means in conjunction with 
Tukey post hoc analysis for the separation of 
means.  P < 0.05 is considered to be statistically 
different. Paired t-tests performed on calculator 
at www.graphpad.com. To determine IC50 
values, data were log-transformed and plotted 
versus drug concentration, followed by 
appropriate graphic analysis as described 
previously [11]. Results were identical when 
1C50 values were determined using Probit 
analysis. 
 
3. RESULTS AND DISCUSSION 
 
Previous research showed that QE from black 
tea has anti-carcinogenic and chemo-preventive 
properties. QE was demonstrated to reduce the 
viability of MDA-MB-231 cells in a dose and time 
dependant manner [6,7,12,13]; QE is indicated in 
the literature as a promising anti-cancer agent 
[13]. Epigallocatechin gallate (EGCG), which 
comprises ~30% of the antioxidants in green tea, 
was found to have chemo-preventative 
properties [6,7]. In tests using MDA-MB-231 (ER-) 
cells, EGCG showed synergistic effects in 
combination with selective estrogen receptor 
modulators [7]. The aim of the current study was 
to examine the effect of EGCG and QE on 
methotrexate cytotoxicity and oxidative stress in 
a naturally resistant breast cancer cell line.  Cell 
response to treatment with methotrexate, EGCG 
and QE alone is shown in Fig. 1. 
 
3.1 Effect of Methotrexate and Tea 
Phenols on Breast Cancer Cell 
Viability  
 
Using data from Fig. 1, the concentrations of 
methotrexate, QE or EGCG leading to a 50% 
decline in viability (IC50) were determined for 
MDA-MB-231 cells treated with each agent 
separately, when assayed using the MTT cell 
proliferation assay. From Table 1 the IC50 value 
for methotrexate was significantly lower when 
compared to values for QE (P = 0.002) or EGCG 
(P= 0.006). There are no previous IC50 values for 
methotrexate, QE, or EGCG determined within a 
single study. However, different investigators 
reported the IC50 for methotrexate using MDA-
MB-231 cells was 80 µM at 24 hours of drug 
treatment where a soluble analogue of MTT was 
the cell proliferation assay [14]. To our 
knowledge no previous reports using resazurin to 
assess methotrexate effect on MDA-MB-231 
cells has been published. 
 
 
Table 1. Inhibition of MDA-MB-231 breast 
cancer cells by methotrexate and tea phenols 
 
MTT assay IC50 (x 10
-6
 M) p 
Methotrexate  35.0±4.0* - 
QE  68.0±9.4  0.002 
EGCG  83.0±16  0.006 
Resazurin assay IC50(x 10
-6 M)  
Methotrexate  55.5±3.5* - 
Methotrexate-QE   40.1±4.5  0.009 
Methotrexate-
EGCG  
46.8±5.8  0.203 
Notes: * significant difference of MTT assay or 
resazurin fluorescence results. QE = quercetin, EGCG 
= epigallocatechin gallate, data shows means ± SEM 
 
The IC50 of QE using MDA-MB-231 cells was 278 
µM after 24 hours of treatment [11] whilst the 
IC50 value of EGCG using MDA-MB-231 cells 
was 87 µM or 109 µM for 24 or 48 hours of 
treatment, respectively [6]; these investigations 
using tea phenols and MDA-MB-231 cells 
employed MTT as cell proliferation assay [6,11]. 
Accordingly, past literature IC50 values based on 
MTT cell proliferation assay were larger 
compared to IC50 values in the present study 
probably because of the longer incubation time 
(72 hours) used (Table 1). 
 
In Fig. 1, cell viability was calculated as 
described previously [11] using the relation; Cell 
viability (%) = (Nt/ N0)*100, where Ntis the cell 
number with drug treatment and N0 is the cell 
number with media only (zero drug concentration) 
treatment. Fig. 1 shows that low concentrations 
of methotrexate, QE or EGCG were stimulatory 
compared to 100% viability observed with cells 
treated with culture media only. Cytotoxicity 
occurred at > 10 µM and methotrexate was more 
effective when compared to QE and EGCG 
(Table 1). U-shaped hormesis drug dose-
responses have been reported in breast cancer 
cell lines treated with QE, ECGC, daidzein, 
resveratrol, plant phytochemicals and drugs [15]. 
Interestingly, we found the IC50 changed with the 
method for assessing residual viable cell number 
after drug treatment. The IC50 value for 
methotrexate determined using the resazurin 
fluorescence assay for cell viability was 55.5±3.5 
µM and significantly different (P<0.001) from the 
IC50 value based on the MTT assay (Table 1). 
For convenience, fluorescence instrumentation 
was adopted for investigations of methotrexate 
interactions with tea phenols (resazurin assay) 
as well as for monitoring changes in ROS (DCHF 
assay, Section 2.5). 
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3.2 Effect of Polyphenol Pre-treatment 
and Methotrexate on Breast Cancer 
Cell Viability 
 
Previous investigations using MDA-MB-231 
demonstrated that tea phenols increase the 
susceptibility of MDA-MB-231 cells to certain 
cancer drugs [8]. In this study, MDA-MB-231 
cells were pre-treated with 10 µM of QE or 
ECGC for 5 hours followed by methotrexate for 
72 hours. The methotrexate dose-response 
curves were then analysed to determine IC50 
values (Table 1, lower half). In breast cancer 
cells pre-treated with QE there was a significant 
(P<0.01) decline in the IC50 value for 
methotrexate by 28% (Table 1). For cells pre-
treated with EGCG the IC50 value for 
methotrexate declined by 16% but did not reach 
significance. These initial findings suggest tea 
phenols may enhance the effectiveness of 
methotrexate though more work will be needed 
to substantiate this effect.  
 
3.3 Methotrexate and Polyphenol Effects 
on Breast Cancer Cell ROS 
 
To get a better insight into how tea phenols affect 
breast cancer cells, we examined changes in 
intracellular levels of ROS with and without drug 
treatment. There were significant rises in 
intracellular ROS for MDA-MB-231 cells pre-
treated with 10 µM concentrations of QE or 
EGCG for 5 hours, followed by cell washing to 
remove the external phenols, and 72 hour 
treatment with 0-100 µM of methotrexate. The 
results in Fig. 2 show that the concentration of 
ROS increased by 50% and 300% following 
treatment with 10 µM or 100 µM methotrexate 
compared to a non-treated control. Pre-treatment 
with QE or ECGC seemed to produce slightly 
greater rises of ROS when cells were 
subsequently treated with methotrexate. Under 
the conditions of these tests, QE or EGCG 
seemed to act as pro-oxidants and there was no 
evidence for a direct antioxidant effect. 
 
Fig. 3 shows the changes of intracellular ROS for 
MDA-MB-231 cells preloaded with DCFH-DA and 
then treated with non-toxic doses (1 uM) of 
methotrexate, QE, or EGCG and combinations of 
these agents for 60 minutes. Interestingly, low 
doses of QE, EGCG and methotrexate produced 
increases in intracellular ROS compared with the 
cells exposed to culture media only (control). 
According to Fig. 3, the ROS levels decreased in 
the sequence: media < MTX+EGCG = MTX+QE 
< MTX <QE < EGCG. The effect of EGCG alone 
was significantly higher than MTX+EGCG (Fig. 
3). The results suggest that pre-treatment with 
QE or EGCG could ameliorate ROS formation in 
response to MTX but more research is needed to 
confirm this. There were no significant changes
 
 
 
Fig. 1. The effects of methotrexate (MTX), quercetin (QE) or epigallocatechin gallate (EGCG) on 
MDA-MB-231 breast cancer cell viability 
Bars show average values from three independent experiments with N = 18 pooled observations with ± standard 
error of the mean. Different letters at each concentration show significantly different results across all treatments 
in this study, n= 18for each treatment (P<0.05). Treatment time was 72 hrs 
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Fig. 2. The effect of breast cancer cell treatment with quercetin (QE) or epigallocatechin gallate 
(EGCG) on methotrexate induced reactive oxygen species (ROS) measured using 2’, 7’
dichlorofluorescin diacetate (DCFH
Cells were treated with 10 µM of QE and EGCG for 5 hours, followed by 72 hour methotrexate drug test  n=18
each treatment. Different letters show significantly different results across al
 
Fig. 3. The effect of combination treatment 
epigallocatechin gallate (EGCG) and methotrexate on intracellular reactive oxygen species 
(ROS) measured using 2’, 7’-dichlorofluorescin diacetate (
MDA-MB-231 cells were treated for 60 
N = 18 pooled observations ± standard error of the mean. 
subsets of data identified by SPPS post
 
in intracellular GSH for any treatments (data not 
shown). Decreases of GSH may occur in cells 
due to rising oxidative stress. However pro
oxidant agents such as QE and EGCG may also 
increase GSH and hence the overall response is 
less predictable. Though plant phytochemicals 
behave as antioxidants in-vitro, these agents 
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-DA) as intracellular probe 
l treatments in this study (P<
 
with quercetin (QE) and methotrexate
DCFH-DA) as intracellular probe
min. bars show average values from three independent experiments with 
Different letters at each concentration show different 
-hoc analysis (P<0 .05) 
-
often show low levels of bioavailability and levels 
in the circulation or tissues are insufficient to 
account for a direct antioxidant effect.  It has 
been suggested that low levels of 
phytochemicals and oxidation products may 
produce “indirect” adaptive response, .e.g. 
induction of antioxidant enzymes in cells [16]
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4. CONCLUSION 
 
This study confirmed that methotrexate was 
cytotoxic for MDA-MB-231 cells and that this cell 
line is more resistant compared to the non-
resistant breast cancer cell lines such as MCF-7 
with a reported IC50 value of 0.9 µM (14). QE and 
EGCG are also cytotoxic to MDA-MB-231 but 
with lower efficacies compared to methotrexate 
according to their IC50 values (Table 1). A 5-hour 
pre-treatment with QE or EGCG prior to 
methotrexate decreased the IC50 value for 
methotrexate by 28% (QE) or 16% (EGCG) 
indicating tea phenols may augment the effects 
of methotrexate.  Measurements of ROS showed 
methotrexate, QE and EGCG had a pro-oxidant 
effect in the cells. However, the rise of ROS was 
lower following combination treatment using 
methotrexate with ECGC. Under the conditions 
of the present study, GSH levels were not 
significantly affected. The initial hypothesis 
appears to be supported by the current finding, 
i.e. tea polyphenols show an enhancing effect 
towards methotrexate cytotoxicity that has been 
reported for other systems [8,9]. 
 
In speculating on the wider implications of the 
current preclinical studies, consumption of tea is 
unlikely to adversely affect methotrexate therapy. 
However, more research is needed into the 
conditions required to optimize favourable 
interactions between tea polyphenols and 
methotrexate particularly since the former 
polyphenols are unstable under the conditions 
typically employed in culture [16]. In the longer 
term, enhancement of methotrexate by tea 
phenols would offer opportunities for revitalizing 
the use of an already established drug without 
further additional drug approval costs. 
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